RobbieMajznerMD

PubMed

• 8 citations
  Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Fo...
  Sarah B. Whittle, Katharine Offer, Ryan D. Roberts, Amy K. LeBlanc, Cheryl A. London
  Pediatric Blood & Cancer. 2021-06-16
• 290 citations
  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
  Jay Y. Spiegel, Shabnum Patel, Lori Muffly, Nasheed Hossain, Jean Oak
  Nature Medicine. 2021-07-26
• 392 citations
  GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
  Robbie G Majzner, Sneha Ramakrishna, Kristen W Yeom, Shabnum Patel, Harshini Chinnasamy
  Nature. 2022-03-01

Journal Articles

• Tumor Antigen Escape from CAR T-cell Therapy  
  Crystal L Mackall, Robbie G Majzner, Clinical Cancer Research

Abstracts/Posters

• Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction
  Robbie G. Majzner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
  Robbie G. Majzner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• CAR T Cell Therapy for Neuroblastoma
  Robbie Majzner, MD, Frontiers in Neurology, Orlando, FL, 12/9/2019